Supernus Pharmaceuticals Inc (SUPN) : Juncture Wealth Strategies reduced its stake in Supernus Pharmaceuticals Inc by 5.38% during the most recent quarter end. The investment management company now holds a total of 60,816 shares of Supernus Pharmaceuticals Inc which is valued at $1,263,148 after selling 3,459 shares in Supernus Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Jul 14, 2016.Supernus Pharmaceuticals Inc makes up approximately 0.89% of Juncture Wealth Strategies’s portfolio.
Other Hedge Funds, Including , Hamilton Lane Advisors sold out all of its stake in SUPN during the most recent quarter. The investment firm sold 23,812 shares of SUPN which is valued $515,530.Cutler Group Lp reduced its stake in SUPN by selling 5,500 shares or 85.86% in the most recent quarter. The Hedge Fund company now holds 906 shares of SUPN which is valued at $19,615.Franklin Street Advisors Inc Nc reduced its stake in SUPN by selling 8,200 shares or 7.16% in the most recent quarter. The Hedge Fund company now holds 106,375 shares of SUPN which is valued at $2,303,019. Supernus Pharmaceuticals Inc makes up approx 0.42% of Franklin Street Advisors Inc Nc’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in SUPN in the latest quarter, The investment management firm added 6,407 additional shares and now holds a total of 11,478 shares of Supernus Pharmaceuticals Inc which is valued at $242,301.
Supernus Pharmaceuticals Inc closed down -1.07 points or -4.90% at $20.77 with 9,78,785 shares getting traded on Monday. Post opening the session at $20.27, the shares hit an intraday low of $20.26 and an intraday high of $21.17 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.08 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.09. The company had revenue of $43.00 million for the quarter, compared to analysts expectations of $45.32 million. The company’s revenue was up 53.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.02 EPS.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 18, 2016. Supernus Pharmaceuticals Inc was Downgraded by Northland Capital to ” Market Perform” on Jul 18, 2016.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.